01 / THE SCENEThe molecule that watches the clock
Somewhere in a Boston lab, a radiochemist is timing a molecule. Not its journey to a tumor - that part is almost solved - but its exit. How long it lingers in healthy tissue before clearing out. In radiopharmaceuticals, the difference between a cure and a side effect is measured in hours of dwell time, and Ratio Therapeutics has built its entire company around getting that number right.
Ratio is a clinical-stage biotech with roughly 76 people, two proprietary platforms, and a partner list that reads like a pharma industry seating chart: Novartis, Bayer, Lantheus, Merck, Bristol Myers Squibb. It does not sell a drug yet. It sells something rarer - a way to design radioactive medicines that are predictable.
02 / THE TENSIONRadiation is a blunt instrument
For a century, the deal with radiation therapy has been a grim compromise: aim it at the cancer, accept that healthy tissue takes the hit too. Targeted radiopharmaceuticals promised to fix that - attach the radiation to a molecule that only binds tumors, and the poison goes where it should. Elegant in theory.
In practice, the molecule still has to travel through the bloodstream, and biology has opinions about how long things stay there. Clear too fast and the tumor never gets a lethal dose. Clear too slow and the kidneys and marrow pay for it. The targeting was solved years ago. The timing was not.
That is the tension running through everything Ratio does. Not "can we find the tumor" but "can we control the visit." It is a less glamorous problem, which is exactly why it stayed open long enough for a small Boston team to make it their entire reason for existing.
03 / THE BETTwo scientists, one previous rodeo
Ratio was founded in 2021 by Jack Hoppin and John Babich - not first-timers stumbling into oncology, but a pair who had already built and validated this style of platform once before. Babich, who serves as President and Chief Science Officer, carried the underlying chemistry out of his research at Weill Cornell. Hoppin took the CEO seat and the harder job of convincing big pharma that timing was worth paying for.
Their bet was almost contrarian: instead of chasing one hero drug, build the machinery to make many. A platform that treats pharmacokinetics as a design parameter you dial, not a fate you accept. It is the kind of bet that sounds modest at a conference and turns out to be the whole game.
The structure is deliberate. Ratio takes candidates from discovery through early clinical proof, then hands the expensive, slow work of late-stage trials and manufacturing to partners who already have the machinery. It keeps the company small and the science central. A 76-person team does not run global Phase 3 programs. It does not have to. It runs the part where the chemistry is still the hard problem.
04 / THE MACHINERYTrillium, Macropa, and a clever use of albumin
The flagship is Trillium, a tri-functional scaffold - three jobs in one molecule. One arm binds the tumor target. One carries the radioactive payload. The third reaches out and grabs albumin, the most abundant protein in your blood, and uses it as a built-in timer. Hold albumin tighter, circulate longer. Let go sooner, clear faster. The half-life becomes a knob.
Trillium
The three-armed scaffold. Binds the target, carries the isotope, and reversibly grips albumin to tune how long the drug stays in circulation.
Macropa
A chelator built to cage large alpha-emitters like actinium-225 securely enough to ride to the tumor without leaking en route.
RTX-1363S
A high-affinity FAP inhibitor, first labeled with copper-64 for PET imaging, now advancing into Phase 1/2 therapy in aggressive sarcomas.
Three molecular arms doing three jobs. The third one - the albumin grip - is the part nobody else was paying enough attention to.
Macropa solves a quieter problem. Alpha-emitting radionuclides like actinium-225 are devastating to cancer cells - a single decay chain can shred DNA - but only if they actually arrive. Lose the isotope mid-transit and you have just irradiated something you did not mean to. Macropa is the cage that keeps the cargo where it belongs.
Together the two platforms cover the theranostic ambition that defines modern radiopharma: design one molecule you can image with a diagnostic isotope, then swap in a therapeutic isotope and treat the same target you just saw light up on a scan. The lead candidate, RTX-1363S, walks exactly that path - it began as a copper-64 PET imaging agent for fibroblast activation protein, a marker found in the stroma of many solid tumors, before moving toward therapy. See it, then treat it. The platform is built so the seeing and the treating are the same molecule wearing different payloads.
The Ratio Timeline
Ratio launches
Hoppin and Babich spin out of prior work, setting up shop in Boston's Design Center to build radiopharmaceuticals around pharmacokinetic control.
$20M Series A
Schusterman and Duquesne back the platform thesis, funding the first push toward the clinic.
First patient dosed
With Lantheus and PharmaLogic, Ratio doses the first patient in a Phase I PET imaging study of its FAP-targeted agent.
$50M Series B
Returning investors plus Bristol Myers Squibb and Cornell's licensing arm push total funding past $90M.
The Novartis deal
A license and collaboration agreement worth up to $745M for an SSTR2-targeted radiotherapeutic. Novartis takes the wheel on development.
Into therapy
The FAP program graduates from imaging to a Phase 1/2 therapeutic study in late-stage aggressive sarcomas.
05 / THE PROOFBig pharma does not write checks for vibes
The clearest evidence that Ratio's timing thesis holds water is who is buying it. The November 2024 Novartis agreement - up to $745M in upfront and milestone payments plus tiered royalties - is not a vote of confidence in a single molecule. It is a vote for the platform that makes molecules.
Funding, in order of nerve
The partner roster is the other tell. Novartis, Bayer, Lantheus, Merck and Bristol Myers Squibb do not collaborate with platforms they think are noise. Each relationship is a separate company looking at Ratio's chemistry and deciding it is worth attaching a program to. The Novartis collaboration specifically targets SSTR2, a receptor relevant in neuroendocrine tumors, with Novartis leading development, manufacturing and commercialization once a candidate is identified - the clearest signal yet that the platform produces things worth taking all the way to market.
06 / THE MISSIONMake the radioactive predictable
Ratio's stated mission is to accelerate next-generation precision radiopharmaceuticals for solid tumors and shift how oncology gets treated. Underneath the corporate phrasing is a simpler ambition: take a class of medicine that has always been a little wild - radiation, after all - and make it behave.
Solid tumors are where most cancer deaths happen and where targeted radiation has struggled most. If you can reliably dose a tumor to lethality while sparing the patient, you change what counts as treatable. That is the prize, and it is why a company that mostly sells chemistry and timing can command nine-figure deals.
07 / TOMORROWThe timer, still running
Radioligand therapy is having a moment - every major pharma is buying into the space, and the molecules getting attention are increasingly the ones with controllable behavior, not just clever targeting. Ratio sits exactly there, having bet years ago on the part of the problem everyone else treated as an afterthought.
Back in that Boston lab, the radiochemist is still timing molecules. But the clock matters differently now. The question is no longer whether dwell time can be controlled - Ratio's partners have already paid to find out. The question is how many cancers that control can reach. The targeting was always the easy part. The timing was the company.